|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
1996-8-21
|
|
pubmed:abstractText |
Mazapertine is a structurally novel antipsychotic compound with high affinity for D2, D3, 5-HT1a, and alpha 1 receptors. The objectives were to determine whether tolerance to orthostatic hypotension caused by this compound could be induced by slowly increasing the dose administered and to investigate its effect on cognitive and motor functions.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0009-9236
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
675-85
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:8681493-Administration, Oral,
pubmed-meshheading:8681493-Adult,
pubmed-meshheading:8681493-Antipsychotic Agents,
pubmed-meshheading:8681493-Chromatography, High Pressure Liquid,
pubmed-meshheading:8681493-Cognition,
pubmed-meshheading:8681493-Dopamine Antagonists,
pubmed-meshheading:8681493-Dose-Response Relationship, Drug,
pubmed-meshheading:8681493-Double-Blind Method,
pubmed-meshheading:8681493-Drug Tolerance,
pubmed-meshheading:8681493-Half-Life,
pubmed-meshheading:8681493-Hemodynamics,
pubmed-meshheading:8681493-Humans,
pubmed-meshheading:8681493-Hypotension, Orthostatic,
pubmed-meshheading:8681493-Male,
pubmed-meshheading:8681493-Middle Aged,
pubmed-meshheading:8681493-Piperazines,
pubmed-meshheading:8681493-Psychomotor Performance
|
|
pubmed:year |
1996
|
|
pubmed:articleTitle |
Incremental dosage of the new antipsychotic mazapertine induces tolerance to cardiovascular and cognitive effects in healthy men.
|
|
pubmed:affiliation |
Clin-Pharma Research AG, Birsfelden, Switzerland.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|
